콘텐츠로 건너뛰기
Merck

SML3953

Istaroxime hydrochloride

≥98% (HPLC)

동의어(들):

Androstane-3,6,17-trione, 3-[O-(2-aminoethyl)oxime], hydrochloride (1:1)

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C21H32N2O3·HCl
CAS 번호:
Molecular Weight:
396.95
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의


Quality Level

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Positive inotropic agent that inhibits Na + /K + -ATPase and increases activity of Ca 2+ -ATPase at the sarcoplasmic reticulum.



Istaroxime is a positive inotropic agent that inhibits Na + /K + -ATPase and increases activity of Ca 2+ -ATPase at the sarcoplasmic reticulum. It improves cardiac performance in the failing heart. Istaroxime ameliorates calcium dysregulation Zebrafish PLN R14del arrhythmogenic cardiomyopathy model.

Disclaimer

Hygroscopic


pictograms

Health hazard

signalword

Warning

hcodes

Hazard Classifications

STOT RE 2

target_organs

Gastro-intestinal system,Heart

저장 등급

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문



SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy
Cardiovascular Research, 118(4), 1020-1032 (2022)
Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure
The American Journal of Cardiology, 99(2A), 24A-32A (2007)
S M Kamel et al.
Nature communications, 12(1), 7151-7151 (2021-12-11)
The heterozygous Phospholamban p.Arg14del mutation is found in patients with dilated or arrhythmogenic cardiomyopathy. This mutation triggers cardiac contractile dysfunction and arrhythmogenesis by affecting intracellular Ca2+ dynamics. Little is known about the physiological processes preceding induced cardiomyopathy, which is characterized